ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bupivacaine

Also written as “HTX-011”, “SKY0402” and “Bupivacaine HCl”.

Its studies are mostly in Pain, Postoperative · Pain · Hernia, Inguinal · Bunion · Hemorrhoids, led by 10 companies.

Drug pageBupivacaine: every studyMany companies study it; this page follows only the 56 they lead. All 1,200 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 24, 201156 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciencesits history only230 open or runningphase 4since Oct 24, 2011Jun 11, 2007none ahead
Heron Therapeuticsits history only171 open or runningphase 4since Oct 10, 2018Jun 9, 2015none ahead
Innocoll60 open or runningphase 3since Aug 12, 2015Oct 18, 2010none ahead
Bausch Health Companiesits history only20 open or runningphase 3since Oct 9, 2015Mar 30, 2010none ahead
Cristália Produtos Químicos Farmacêuticos Ltda.its history only20 open or runningphase 3since Feb 23, 2011Feb 23, 2011none ahead
Jiangsu HengRui Medicineits history only22 open or runningphase 4since Mar 13, 2024Mar 13, 2024Nov 2026phase 2 · NCT06529432
Ascension Healthits history only10 open or runningphase 3since Nov 20, 2019Nov 20, 2019none ahead
Liquidia Technologiesits history only10 open or runningphase 1since Nov 22, 2016Nov 22, 2016none ahead
Rebel Medicineits history only11 open or runningphase 2since Apr 28, 2026Apr 28, 2026none ahead
Tian Medicalits history only10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: Pfizer, Premier Research Group and Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2010First study: phase 2 study in HerniaFirst studyNCT01224145 · 10 enrolled · United States
  2. Aug 12, 20152 phase 3 studies in Pain, PostoperativeNCT02525133, NCT02523599
  3. Aug 21, 2017Phase 3 study in Hernia, InguinalNCT03262688 · 159 enrolled · United States
  4. Mar 1, 20212 phase 3 studies in Pain, PostoperativeNCT04785638, NCT04785625

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Innocoll leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04785638Pain, Postoperative · United States3CompletedJan 10, 2023100
NCT04785625Pain, Postoperative · United States3CompletedOct 27, 2021366
NCT03262688Hernia, Inguinal · United States3UNKNOWNJan 31, 2024159
NCT02525133Pain, Postoperative · United States3CompletedApr 22, 2016319
NCT02523599Pain, Postoperative · United States3CompletedApr 2016305
NCT01224145Hernia · United States2CompletedJun 20, 201110

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “SKY0402”, 12 entries
  • “Bupivacaine HCl”, 7 entries
  • “Bupivacaine”, 5 entries
  • “Bupivacaine Liposome Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.